GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT07489287
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GB-5267 - IV only — BIOLOGICAL
    IV infusion
  • GB-5267 -Combined IV and IP Infusion — BIOLOGICAL
    IV and IP Infusion

Study Details

This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.

Key Dates

Start date
Jun 15, 2026
Status verified
Jun 2026
Primary completion
Jan 15, 2028
Completion
Jan 15, 2030

Study Design

Enrollment
18 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: IV Only
    Patients receive IV only infusion of GB-5267 cells
  • Experimental: Dose Expansion with Combined IV and IP Infusion
    A combined administration of both IV and IP infusions.

Primary Outcome Measure

Maximum Tolerated Dose (MTD) - Cohort A [ Time Frame: 28 days from GB-5267 cell infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIP
Roswell Park Comprehensive Cancer CenterBuffaloNew York14263

Find similar trials in Buffalo, NY

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Roswell Park Comprehensive Cancer Center· Buffalo, NY

Related Studies